Obesity Market Intelligence Newsletter
To help you stay up to date with the latest clinical, commercial, and regulatory changes, Airfinity is launching a free weekly newsletter compiling all the information and analysis you need to inform your strategies.
Whether you have a candidate in clinical trials, are looking to understand uptake and the role payers should be playing, or even want to know how the wider anti-obesity treatment market is impacting other industries, sign up today to ensure you stay ahead of the curve.
Clinical: What does the current pipeline look like, from pre-clinical through to post-approval? What are the latest safety and efficacy data and how do they compare to competing candidates?
Commercial: What does current manufacturing capacity look like and how might anticipated demand impact future production efforts?
Regulatory: Are we seeing any shifts in drug pricing regulations or reimbursement policies? What is being done to control and prevent counterfeit or substandard medications from entering the market?
Health Economics and Disease Outcomes: What is the latest analysis and understanding around the wider economic impact of current anti-obesity drugs, and their role in reducing disease burden across other CVRM diseases?
Sign up today!
Fill out this short form to be instantly added to our newsletter.
Sign up today!
Fill out this short form to be instantly added to our newsletter.
What our users say?
“The Airfinity report is a guide for world leaders to fix a more ambitious action plan.”
Gordon Brown, WHO Ambassador for Global Health Financing & former UK Prime Minister
“Airfinity has been instrumental in our country's COVID response.”
Head of UK Government
Vaccine Task Force
In a dynamic environment, Airfinity enabled us to remain on track with daily developments to enable more accurate decision-making. Airfinity combines nimbleness of real time data and their group of scientists that can analyse, model and provide strategic analysis for critical decision making.”
Iskra Reic, Executive Vice-President
Astrazeneca
“Probably the most expansive, accurate and helpful of the multiple data sets on an international scale”
Sir John Bell ,
University of Oxford